More importantly, MEnZn‐CuO NPs significantly increased the therapeutic sensitivity of ovarian cancer cells to the PARP inhibitor Olaparib by inhibiting the cellular HR repair ability. The gene discussed is PARP1; the disease is ovarian cancer.